Business
Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
GENEVA, August 19, 2025--Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
About this update from Alcon Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":202,"url":"https://media.zenfs.com/en/business-wire.com/1309f5c5a7dbe065fffd1ee97fe6d785"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/laYoJIj3ZbpbQe_Qym1Dmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1309f5c5a7dbe065fffd1ee97fe6d785","width":480,"height":202}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024","length":130,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76","length":68,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders","length":146,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US","length":84,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction","length":98,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":526,"olType":false},{"type":"text","content":"Ad Hoc Announcement Pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"GENEVA, August 19, 2025--(BUSINESS WIRE)--Regulatory News:","length":58,"tagName":"p"},{"type":"text","content":"Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2025. For the second quarter of 2025, sales were $2.6 billion, up 4% on a reported basis and up 3% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.35 and core diluted earnings per share2 of $0.76 in the second quarter of 2025.","length":447,"tagName":"p"},{"type":"text","content":""Alcon is exiting the second quarter with solid momentum, despite a relatively soft surgical market in the first half of the year," sa...